title: In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
abstract: Voriconazole, anidulafungin (VER002, LY303366) and caspofungin are promising antifungal agents which provide a good protection against a variety of fungi, including yeasts and filamentous fungi. In this study, we tested the in vitro efficacy of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B, against different species of Aspergillus spp. isolated from clinical specimens, using a microdilution broth method and following the NCCLS guidelines (document M38-P). We also evaluated the effect that time readings have on MIC results. For caspofungin, we determined the minimun effective concentration (MEC), defined like the lowest concentration of caspofungin causing abnormal hyphal growth. Anidulafungin (VER002, LY303366) was the most active antifungal agent tested with MIC(90) of < or =0,03 mg/L. The activity of voriconazole, and itraconazole very similar with MIC(90) of 0,12 mg/L, 0,12 mg/L respectively. For caspofungin the MEC(90) was of 0,25 mg/L. Amphotericin B was the lest active antifungal agent studied with MIC(90) of 1 mg/L. There were no differences between MIC values at 48 and 72 h. These data demonstrate promising activity of voriconazole, anidulafungin (VER002, LY303366) and caspofungin against Apergillus spp.
authors.affiliation: Servicio de Microbiología Clínica, Hospital Universitario de Valme, Sevilla, Spain.
authors.forename: María del Carmen
authors.initials: Mdel C
authors.lastname: Serrano
authors.forename: Anastasio
authors.initials: A
authors.lastname: Valverde-Conde
authors.forename: Mónica
authors.initials: M
authors.lastname: Chávez M
authors.forename: Samuel
authors.initials: S
authors.lastname: Bernal
authors.forename: Rosa María
authors.initials: RM
authors.lastname: Claro
authors.forename: Javier
authors.initials: J
authors.lastname: Pemán
authors.forename: Mercedes
authors.initials: M
authors.lastname: Ramirez
authors.forename: Estrella
authors.initials: E
authors.lastname: Martín-Mazuelos
mesh_terms: D000666:Amphotericin B / Q000494:pharmacology; D000077612:Anidulafungin; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D001230:Aspergillus / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D000077336:Caspofungin; D054714:Echinocandins; D006801:Humans; D017964:Itraconazole / Q000494:pharmacology; D055666:Lipopeptides; D008826:Microbial Sensitivity Tests; D010455:Peptides; D010456:Peptides, Cyclic / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D013997:Time Factors; D014230:Triazoles / Q000494:pharmacology; D065819:Voriconazole
chemical_list: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; D017964:Itraconazole; D000666:Amphotericin B; D000077612:Anidulafungin; D000077336:Caspofungin; D065819:Voriconazole